Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterised by scarring of the lung that is believed to result from an atypical response to injury of the epithelium. The mechanisms by which this arises are poorly understood and it is likely that multiple pathways are involved. The strongest genetic association with IPF is a variant in the promoter of MUC5B where each copy of the risk allele confers a five-fold risk of disease. However, genome-wide association studies have reported additional signals of association implicating multiple pathways including host defence, telomere maintenance, signalling and cell-cell adhesion.
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IPF is associated with a number of environmental and genetic factors. Identifying regions of the genome contributing to disease risk improves our understanding of the biological processes underlying IPF and helps in the development of new treatments 3 . To date, genome-wide association studies [4] [5] [6] [7] [8] (GWAS) have reported 17 common variant (minor allele frequency [MAF]>5%) signals associated with IPF; stressing the importance of host defence, telomere maintenance, cell-cell adhesion and signalling with respect to disease susceptibility. The sentinel (most strongly associated) variant, rs35705950, in one of these signals that maps to the promoter region of the MUC5B gene, has a much larger effect on disease susceptibility than other reported risk variants with each copy of the risk allele associated with a five-fold increase in odds of disease 9 . Despite this, the variant rs35705950 has a risk allele frequency of 35% in cases (compared to 11% in the general population) and so does not explain all IPF risk. Rare variants (MAF<1%) in telomere-related and surfactant genes have also been implicated in familial pulmonary fibrosis and sporadic IPF 10, 11 .
In this study, we performed the largest GWAS of IPF susceptibility to date, followed by bioinformatics analysis of gene expression data to identify the genes underlying identified association signals and inform our understanding of IPF pathogenesis and risk. As specific IPF associated variants have also been shown to overlap with other respiratory traits including lung function, chronic obstructive pulmonary disease (COPD) 12, 13 and interstitial lung abnormalities 14 (ILAs, which might be a precursor lesion for IPF), we tested for association of the IPF risk variants with other respiratory phenotypes in independent datasets. Finally, using polygenic risk scores, we tested whether there was a still substantial contribution to IPF risk from genetic variants with as-yet unconfirmed associations with IPF susceptibility.
Methods

Study design
We analysed genome-wide association data from three independent IPF case-control collections. These three studies (named here as the Chicago
5
, Colorado 6 and UK 8 studies) are previously described and comprise of patients with IPF and non-IPF controls (Appendix). Two more casecontrol collections (named here as the UUS [USA, UK and Spain] and Genentech studies) that had not contributed to any previous IPF GWAS were included as a replication dataset. In the UUS study, cases were recruited from across the USA, UK and Spain and controls were selected from UK Biobank to follow a similar sex and smoking distribution seen in the IPF cases (Appendix). The Genentech study consisted of cases from three IPF clinical trials and controls from four non-IPF clinical trials that have been previously described (Appendix) 15 . All five studies restricted to unrelated individuals of European ancestry and we applied stringent quality control measures (Appendix). All studies diagnosed IPF cases using American Thoracic Society and European Respiratory Society guidelines [16] [17] [18] and had appropriate institutional review board or ethics approval.
Procedures and statistical analysis
For this study, genotype data for the Colorado, Chicago, UK and UUS were imputed separately using the Haplotype Reference Consortium (HRC) r1.1 panel 19 (Appendix). Whole-genome sequencing data was available for the Genentech study. Overlap of cases and controls between studies was assessed using KING 20 v2.1.2 (Appendix) to remove duplicate samples.
Identification of IPF susceptibility signals
In each of the Chicago, Colorado and UK studies separately, a genome-wide analysis of IPF susceptibility, using SNPTEST 21 v2.5.2, was conducted assuming an additive genetic effect and adjusting for the first 10 principal components to account for fine-scale population structure. Only bi-allelic autosomal variants that had a minor allele count ≥10 within the study, were in HardyWeinberg Equilibrium (P>10 −6 ) and were well imputed (imputation quality R 2 >0.5) were included.
For identification of genetic signals associated with IPF susceptibility, a fixed effect inverse-variance weighted genome-wide meta-analysis (Figure 1 ) of the IPF susceptibility association summary statistics was performed across the Chicago, Colorado and UK studies using R v3.5.1 (discovery stage). Results were corrected for inflation due to residual fine-scale population structure using genomic control at both the study and meta-analysis level. Only genetic variants represented in at least two studies were included in the discovery analysis. Conditional analyses were performed to identify independent association signals in each locus (Appendix).
Novel signals reaching genome-wide significance and showing nominal significance (P<0.05) with consistent direction of effect in each contributing study were further tested in the replication samples. We considered novel signals to be associated with IPF risk if they reached a Bonferronicorrected threshold (P<0.05 / number of signals followed-up) in a replication meta-analysis of the UUS and Genentech studies (replication stage, Appendix). Previously reported signals reaching genome-wide significance (P<5×10 −8 ) in the discovery meta-analysis were deemed as showing a confirmed association with IPF risk.
Characterisation of signals and functional follow-up
For each association signal the posterior probability of each variant in the region being causal was calculated (assuming there is one causal variant and it has been measured) 22 . From this, a 95% credible set (i.e. the smallest set of variants that is 95% likely to contain the causal variant) was generated for each IPF signal (Appendix). VEP (Variant Effect Predictor) 23 was used to annotate each credible set variant to identify deleterious variants (Appendix).
Linked genotype and gene expression data resources were interrogated to identify putative causal genes for the novel association signals. Variants in the 95% credible sets were investigated in three eQTL databases; a lung eQTL database consisting of individuals from three cohorts (Universities of British Columbia, Laval and Groningen, n=1,111) [24] [25] [26] , the NESDA-NTR (Netherlands Study of Depression and Anxiety and the Netherlands Twin Register) blood eQTL database (n=4,896) 27 and 48 tissue types in GTEx (Genotype-Tissue Expression project, n between 80 and 491) 28 . An FDR threshold of 10% was used for the lung eQTL database and NESDA-NTR, and an FDR threshold of 5% was used for the smaller GTEx resource. Where a variant in a credible set for a novel association signal was found to be an eQTL for a gene, we calculated the posterior probability of the IPF GWAS signal and eQTL signal being driven by the same variant (colocalisation) using coloc 29 . Colocalisation between IPF susceptibility and eQTL signal was defined as when the posterior probability of the IPF GWAS and eQTL signals being driven by the same variant was greater than 80% (Appendix). Only genes where there was colocalisation of the IPF susceptibility and eQTL signal are reported.
The variants with the highest posterior probability of causality for the novel signals were explored using HaploReg v4.1 30 to identify overlap with histone mark promoters and enhancers in relevant tissue (i.e. lung). We used DeepSEA 31 , a deep-learning variant effect predictor, to identify whether any of the IPF risk signals were predicted to have a functional effect on chromatin features and transcription factor binding sites. The IPF risk signals were tested for enrichment in regulatory regions using FORGE 32 and GARFIELD 33 . SNPsea 34 was used to assess enrichment of genes in linkage disequilibrium with IPF risk variants in i) 1,751 genetic pathways and, ii) in genes showing differential expression between IPF cases and controls in four epithelial cell types 35 (Appendix).
Association with other respiratory traits
The variant with the highest posterior probability of causality in the credible set for each IPF risk signal was investigated for its association with measures of lung function 36 and interstitial lung abnormalities (Appendix). Lung function (namely FEV1, FVC, the ratio FEV1/FVC and PEF) was tested in 400,102 individuals 36 . ILA analyses were performed comparing up to 1,699 individuals with any ILA to 10,274 individuals without any ILA; an additional analysis restricted the ILA cases to 1,287 individuals with subpleural ILAs. Variants were reported as associated with lung function or ILA if they met a Bonferroni corrected P value threshold for the number of variants and traits investigated.
Polygenic risk scores
Polygenic risk scores were utilised to assess the contribution of as-yet unreported variants to IPF risk. Polygenic risk scores allow for the cumulative effect of many genetic variants to be studied. The polygenic risk score was equal to the number of risk alleles carried multiplied by the effect size of the variant, summed across all variants included in the score, i.e.:
where βi is the log(OR) of variant i from the genome-wide meta-analysis of the UK, Chicago and Colorado studies, Xij is the genotype of variant i for person j and n is the number of variants. Scores were generated for individuals in the independent UUS study using independent variants selected after LD-clumping (r 2 ≤0.1). This score was tested to identify whether it was associated with IPF susceptibility, adjusting for 10 principal components to account for fine-scale population structure, using PRSice v1.25 37 . As we wanted to explore the contribution to IPF risk from variants not yet reported, we excluded variants within 1Mb of each IPF risk locus identified in this IPF susceptibility GWAS. We altered the number of variants included in the risk score calculation by setting a Pthreshold (PT) criteria such that the variant had to have a P value<PT in the genome-wide metaanalysis to be included in the score. Given multiple testing, we used the recommended significance threshold of P<0.001 for determining significantly associated risk scores 37 .
Results
Following quality control, 541 cases and 542 controls from the Chicago study, 1,515 cases and 4,683 controls from the Colorado study and 612 cases and 3,366 controls from the UK study were available ( Table 1, Supplementary Figure 1) to contribute to the discovery stage of the genome-wide susceptibility analysis. For the replication stage of the GWAS, after quality control, there were 803 cases and 10,000 controls available in the UUS study and 664 cases and 1,874 controls available in the Genentech study (Appendix).
To identify new signals of association, we meta-analysed the genome-wide association results for IPF susceptibility for the Chicago, Colorado and UK studies. This gave a maximum sample size of up to 2,668 cases and 8,591 controls for 10,790,934 well imputed (R 2 >0.5) variants with minor allele count ≥10 in each study and which were available in two or more of the studies (Supplementary Figure 2) . We identified 14 IPF risk signals (11 of which have been previously reported and three were novel, Figure 2 and Supplementary Figure 3) . Conditional analyses did not identify any additional independent association signals at these loci.
We identified three novel signals (in 3p21.31 [near KIF15, Figure 3i ], 7p22.3 [near MAD1L1, Figure  3ii ] and 8q24.12 [near DEPTOR, Figure 3iii] ) that showed an association in the discovery metaanalysis and were also significant after adjusting for multiple testing (P<0.01) in the replication stage comprising 1,467 IPF cases and 11,874 controls. Two additional loci were genome-wide significant in the genome-wide discovery analysis but did not reach significance in the replication studies. The sentinel variants of these two signals were a low frequency intronic variant in RTEL1 (MAF=2.1%, replication P=0.012) and a rare intronic variant in HECTD2 (MAF=0.3%, replication P=0.155) ( Table 2,  Supplementary Table 1 , Supplementary Figures 5 and 6 ).
For the novel signal on chromosome 3, the sentinel variant (rs78238620) was a low frequency variant (MAF=5%) in an intron of KIF15 with the minor allele being associated with increased susceptibility to IPF. The IPF susceptibility signal was associated with decreased expression of KIF15 in brain tissue and the nearby gene TMEM42 in thyroid (Supplementary Figure 7, Supplementary  Tables 2 and 3i ).
In the statistical fine-mapping of the novel signal on chromosome 7, the sentinel variant (rs12699415, in an intron of MAD1L1) had a much higher posterior probability of causality for IPF (36%) compared to the other variants in the credible set for that signal (all others had probability<4%). The IPF susceptibility signal was associated with decreased expression of MAD1L1 in heart tissue (Supplementary Figure 8, Supplementary Tables 2 and 3ii ).
For the signal on chromosome 8, the sentinel variant (rs28513081) was located in an intron of DEPTOR. The fine-mapping analysis identified 95 variants in the 95% credible set (all located in introns of DEPTOR) each contributing <5% posterior probability of causality. The IPF risk allele was associated with decreased expression of DEPTOR in colon, lung (in both the lung eQTL database and GTEx) and skin. The allele was also associated with increased expression of DEPTOR in the NESDA-NTR database (whole blood), increased expression of TAF2 (in colon), RP11-760H22.2 (increased in adipose, and decreased in colon, and lung) and increased expression of KB-1471A8.1 (in adipose and skin, Supplementary Figure 9, Supplementary Tables 2 and 3iii ).
We confirmed genome-wide significant associations with IPF susceptibility for 11 of the 17 previously reported signals (in or near TERC, TERT, DSP, 7q22.1, MUC5B, ATP11A, IVD, AKAP13, KANSL1, FAM13A and DPP9; Supplementary Table 1, Supplementary Figure 4) . Three further signals at 11p15.5 (near MUC5B) were no longer genome-wide significant after conditioning on the MUC5B promoter variant (Supplementary Table 1) , consistent with previous reports 6 
.
Of the 14 IPF risk signals (i.e. the 11 previously reported signals we confirmed and three novel signals), the only variant predicted to have a functional effect using DeepSEA was rs2013701 (in an intron of FAM13A), which was associated with a change in DNase in 18 cell types and FOXA1 in the T-47D cell line (a breast cancer cell line derived from a pleural effusion). The 14 IPF risk signals were found to be enriched in DNase I hypersensitivity site regions in foetal lung tissue (Supplementary  Figure 10) . Taking all variants with genome-wide significant (P<5×10 −8 ) association with IPF susceptibility from our discovery analysis, we found enrichment in DNase I hypersensitivity sites in multiple tissues (including foetal lung) (Supplementary Figure 11) . No pathway-specific geneexpression enrichment or enrichment in differential expression in airway epithelial cells between IPF cases and healthy controls was observed for the 14 IPF risk signals when using SNPsea (Supplementary Table 4) .
The sentinel variants of 12 of the 14 IPF risk loci were at least nominally associated (P<0.05) with one or more lung function trait in general population studies (Supplementary Table 5 ). After adjustments for multiple testing (P<5.2×10 −4 ), the previously reported variants at FAM13A, DSP and IVD were associated with decreased FVC and variants at FAM13A, DSP, 7q22.1 (ZKSCAN1) and ATP11A were associated with increased FEV1/FVC. Similarly, for the three novel risk variants, all showed at least a nominal association with decreased FVC and increased FEV1/FVC. We observed a nominally significant association of the MUC5B IPF risk allele with decreased FVC and increased FEV1/FVC. The IPF risk alleles at MAPT were significantly associated with both increased FEV1 and FVC. Eight of the IPF risk loci were at least nominally significantly associated with either ILA or subpleural ILA with consistent direction of effects (i.e. the allele associated with increased IPF risk was also associated with increased ILA risk). The new KIF15, MAD1L1 and DEPTOR signals were not associated with ILA (although the rare risk allele at HECTD2 that did not replicate in our study showed some association with an increased risk of subpleural ILA [P=0.003] with a large effect size similar to that observed in the IPF discovery meta-analysis).
To quantify the impact of as-yet unreported variants on IPF susceptibility, polygenic risk scores were calculated excluding the 14 IPF risk variants (as well as all variants within 1Mb). The polygenic risk scores were significantly associated with increased IPF risk despite exclusion of the known genetic association signals (including MUC5B). The most significant risk score was observed when including variants from the genome-wide discovery meta-analysis with P<0.664 (risk score P=1.41×10 −24 , Supplementary Figure 12 ). This risk score contained 806,476 independent variants and explained approximately 2% of the phenotypic variation (Nagelkerke's R 2 =0.023). These results suggest that there is a significant contribution of additional as-yet undetected common and low frequency variants to IPF susceptibility.
Discussion
We undertook the largest GWAS of IPF susceptibility to date and identified three novel signals of association that implicated genes not previously known to be important in IPF.
The new signal on chromosome 8 implicates DEPTOR, which encodes the DEP Domain containing MTOR interacting protein. DEPTOR inhibits mTOR kinase activity as part of both the mTORC1 and mTORC2 protein complexes. The IPF susceptibility risk allele at this locus was associated with decreased gene expression of DEPTOR in lung tissue. TGF-induced DEPTOR suppression can stimulate collagen synthesis 38 and the importance of mTORC1 signalling via 4E-BP1 for TGFβ induced collagen synthesis has recently been demonstrated in fibrogenesis 39 . The signal on chromosome 8 did also colocalise with expression of TAF2, RP11-760H22.2 and KB-1471A8.1 in similar tissues to DEPTOR. MAD1L1, implicated by a new signal on chromosome 7, is a mitotic checkpoint gene, mutations in which have been associated with multiple cancers including lung cancer 40 . Another spindle-assembly related gene, KIF15, was implicated by the new signal on chromosome 3 (along with TMEM42).
The genome-wide study also identified two signals that were not replicated after multiple testing adjustments. The intronic variant in RTEL1 had the same direction of effect in all five studies and was nominally significant in four studies. Multiple genes of the telomere complex and short telomere length are associated with IPF risk [41] [42] [43] . RTEL1, a gene involved in telomere elongation regulation, has not previously been identified in an IPF GWAS, however the collective effect of rare variants in RTEL1 have been reported as associated with IPF risk [44] [45] [46] [47] . The rare variant in the promoter region of HECTD2 was significantly associated with IPF susceptibility with an OR>7.5 in two out of the three discovery studies, but was unsupported by the replication data. This variant showed some association with subpleural ILA in an independent dataset with a similarly large effect size in the same direction. The ubiquitin E3 ligase encoded by HECTD2 has been shown to have a proinflammatory role in the lung and HECTD2 polymorphisms may be protective against acute respiratory distress syndrome 48 . The inconsistent evidence for an association suggests that further exploration of the relationship of HECTD2 to risk of interstitial lung diseases is warranted.
By combining the largest available GWAS datasets for IPF, we were able to confirm 11 of 17 previously reported signals. Of note, the signal at FAM13A whilst genome-wide significant in the discovery meta-analysis, was not significant in the Chicago study. Conditional analysis at the 11p15.5 region indicated that previously reported signals at MUC2 and TOLLIP were not independent of the association with the MUC5B promoter variant. Previously reported signals at EHMT2, OBFC1 and MDGA2 were found to only be associated in one of the discovery studies and showed no evidence of an association with IPF risk in the other two discovery studies.
The IPF susceptibility signals at DSP, FAM13A, 7q22.1 (ZKSCAN1) and 17q21.31 (MAPT) have also been reported as associated with COPD, although with opposite effects (i.e. the allele associated with increased risk of IPF being associated with decreased risk of COPD). Spirometric diagnosis of COPD was based on a reduced FEV1/FVC ratio. In an independent dataset of 400,102 individuals, eight of the IPF signals were associated with decreased FVC and with a comparatively weaker effect on FEV1. This is consistent with the lung function abnormalities associated with IPF, as well as the decreased risk of COPD. We also showed, for the first time, a modest effect of the MUC5B risk allele on lung function in the general population.
Using polygenic risk scores, we demonstrated that, despite the relatively large proportion of disease risk explained by the known genetic signals of association reported here, IPF is highly polygenic with potentially hundreds (or thousands) of as-yet unidentified variants associated with disease susceptibility. These unidentified variants may have small effect sizes or be of low frequency meaning larger more powerful studies are needed to detect them. However, they could individually and collectively advance our knowledge of IPF risk and disease mechanisms. This motivates the pursuit of larger GWAS of IPF susceptibility through collation of existing and new IPF case-control data sets and through improved analytic approaches.
A strength of our study was the large sample size compared to previous GWAS and the availability of an independent replication data set. A limitation of the study was that the controls used were generally younger in all studies included and there were differences in sex and smoking distributions in some of the studies. As we had limited information beyond IPF diagnosis status for a large proportion of the individuals included in the studies, we cannot rule out some association with other age-related conditions that are comorbid with IPF. It is worth noting however, that individuals with non-IPF diseases were not excluded from the control sets.
In summary, we report new biological insights into IPF risk and demonstrate that further studies to identify the genetic determinants of IPF susceptibility are needed. Our new signals of association with IPF risk provide increased support for the importance of mTOR signalling in pulmonary fibrosis as well as the possible implication of mitotic spindle-assembly genes. ) and variants in green met the criteria for further study in the replication analysis (i.e. reached genome-wide significance in the discovery meta-analysis and had P<0.05 and consistent direction of effects in each study). Genes labelled in grey are previously reported signals that reach significance in the discovery genome-wide meta-analysis. Genes labelled in black are the novel signals identified in the discovery analysis that reach genome-wide significance when meta-analysing discovery and replication samples. The signals which did not replicate are shown by red labels. For ease of visualisation the y axis has been truncated at 25. 
